Current Advances in γδ T Cell-Based Tumor Immunotherapy

Area of Science:

• Immunology
• Oncology
• Cellular Biology

Background:

• γδ T cells are a distinct T cell subset with unique antigen recognition and effector functions.
• Two main subsets, Vδ1 and Vδ2 T cells, exhibit different tissue distribution and antigen specificities.
• Vγ9Vδ2 T cells recognize phosphoantigens (PAgs) and are activated by aminobisphosphonates (n-BPs).

Purpose of the Study:

• To review the achievements and challenges of γδ T cell-based cancer immunotherapy.
• To discuss the potential of γδ T cells as a therapeutic strategy against cancer.
• To evaluate the clinical efficacy and limitations of current γδ T cell immunotherapies.

Main Methods:

• Review of existing literature on γδ T cell biology and immunotherapy.
• Analysis of clinical trial data for γδ T cell-based cancer treatments.
• Discussion of mechanisms of γδ T cell activation and anti-tumor activity.

Main Results:

• γδ T cells possess intrinsic anti-tumor properties, including cytokine production and cytotoxicity, independent of MHC restriction.
• Clinical trials using PAgs or n-BPs with interleukin-2, or adoptive transfer of Vγ9Vδ2 T cells, show safety.
• Current strategies yield inconsistent long-term clinical outcomes, necessitating further optimization.

Conclusions:

• γδ T cell immunotherapy is a safe approach for cancer treatment.
• The inconsistent long-term efficacy of current γδ T cell therapies requires further investigation.
• Optimizing γδ T cell activation and expansion is crucial for improving cancer immunotherapy outcomes.